MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
0.4131
-0.0019
-0.46%
After Hours: 0.4028 -0.0103 -2.49% 19:15 05/19 EDT
OPEN
0.3992
PREV CLOSE
0.4150
HIGH
0.4200
LOW
0.3900
VOLUME
636.24K
TURNOVER
--
52 WEEK HIGH
2.850
52 WEEK LOW
0.3900
MARKET CAP
122.00M
P/E (TTM)
-0.3398
1D
5D
1M
3M
1Y
5Y
1D
Morgan Stanley Keeps Their Hold Rating on Lyell Immunopharma (LYEL)
TipRanks · 17h ago
Weekly Report: what happened at LYEL last week (0512-0516)?
Weekly Report · 21h ago
Lyell Immunopharma reports Q1 results
Seeking Alpha · 5d ago
Lyell Immunopharma Advances CAR T-Cell Therapy Pipeline
TipRanks · 6d ago
Lyell Immunopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 6d ago
Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
Dow Jones · 6d ago
Press Release: Lyell Immunopharma Reports -2-
Dow Jones · 6d ago
Press Release: Lyell Immunopharma Reports -3-
Dow Jones · 6d ago
More
About LYEL
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The Company is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.